By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias
News

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

Last updated: 22/07/2025 1:36 AM
Published: 22/07/2025
Share
SHARE

AUSTIN, Texas, July 21, 2025 /PRNewswire/ — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart’s contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI.

- Advertisement -

“This technology marks a significant advancement in how we care for patients with heart rhythm disorders—particularly those who previously had few viable cardiac resynchronization therapy treatment options,” said Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI. “At the Texas Cardiac Arrhythmia Institute, our commitment is to bring the most advanced, evidence-based therapies to patients worldwide, and as a result of Dr. Canby’s leadership, we successfully delivered on that promise.”

- Advertisement -

The system is the first-ever to stimulate the heart muscle electrically via a small, leadless device—about the size of a grain of rice—that is implanted inside tissue of the left ventricle, the heart’s primary pumping chamber. The device converts ultrasound energy into electrical pulses, restoring the heart’s normal rhythm and pumping efficiency.

- Advertisement -

Traditional cardiac resynchronization therapies involve leads—thin and soft insulated wires about the size of a spaghetti noodle. This left ventricular endocardial pacing device provides a direct approach, which enables more flexible placement and expands access to those who were previously considered untreatable.

- Advertisement -

TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of esteemed cardiac electrophysiologists—led by Dr. Natale, a world-renowned expert in the field—perform a high volume of the most complex electrophysiology procedures.

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/texas-cardiac-arrhythmia-institute-at-st-davids-medical-center-first-in-us-to-use-fda-approved-novel-wireless-system-to-treat-cardiac-arrhythmias-302509006.html

- Advertisement -
2025 International MICE Summit (IMS) to convene global leaders as Vision 2030 powers Saudi Arabia’s rise as a global hub for business events
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
NYSE Content Update: Joby Aviation Rings Opening Bell Following NYC Test Flight
GAC Shines at IAA MOBILITY Munich with AION V Officially Entering Europe, Accelerating the “European Market Plan”
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
TAGGED:arrhythmiaarrhythmiascardiaccenterdavid’sfda-approvedfirstinstitutemedicalnewsnovelst.systemtexastreatu.s.usewireless
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
RiverMeadow Enables Seamless Migration of Workloads to AWS Outposts with Secure, On-Premises Flexibility
News

RiverMeadow Enables Seamless Migration of Workloads to AWS Outposts with Secure, On-Premises Flexibility

22/07/2025
BuzzFeed’s Digital Asset Treasury Strategy and Monetization Efforts Proposed By Edge One Capital
First Participating Phygital Stars for the Games of the Future 2025 in Abu Dhabi Announced
GSMA welcomes China Tower to advance AI-ready mobile infrastructure
NYSE Content Advisory: Pre-Market update + Traders See 55% Chance Fed Holds Rates Steady
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?